Cargando…

The use of a surface active agent in the protection of a fusion protein during bioprocessing

The bioprocessing of a fusion protein is characterised by low yields and at a series of recovery and purification stages that leads to an overall 90% loss. Much of this apparent loss is due to the denaturation of a protein, missing a vital affinity ligand. However, there is evidence of the protectio...

Descripción completa

Detalles Bibliográficos
Autores principales: Blas, Peter, Tolner, Berend, Ward, John, Chester, Kerry, Hoare, Mike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334174/
https://www.ncbi.nlm.nih.gov/pubmed/30102764
http://dx.doi.org/10.1002/bit.26817
_version_ 1783387667082248192
author Blas, Peter
Tolner, Berend
Ward, John
Chester, Kerry
Hoare, Mike
author_facet Blas, Peter
Tolner, Berend
Ward, John
Chester, Kerry
Hoare, Mike
author_sort Blas, Peter
collection PubMed
description The bioprocessing of a fusion protein is characterised by low yields and at a series of recovery and purification stages that leads to an overall 90% loss. Much of this apparent loss is due to the denaturation of a protein, missing a vital affinity ligand. However, there is evidence of the protection of degradation products which occurs in the presence of shear plus air/liquid interfaces. This study seeks out to characterise the loss and use ultra‐scale‐down studies to predict its occurrence and hence shows these may be diminished by the use of protective reagents such as Pluronic F68.
format Online
Article
Text
id pubmed-6334174
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-63341742019-01-23 The use of a surface active agent in the protection of a fusion protein during bioprocessing Blas, Peter Tolner, Berend Ward, John Chester, Kerry Hoare, Mike Biotechnol Bioeng ARTICLES The bioprocessing of a fusion protein is characterised by low yields and at a series of recovery and purification stages that leads to an overall 90% loss. Much of this apparent loss is due to the denaturation of a protein, missing a vital affinity ligand. However, there is evidence of the protection of degradation products which occurs in the presence of shear plus air/liquid interfaces. This study seeks out to characterise the loss and use ultra‐scale‐down studies to predict its occurrence and hence shows these may be diminished by the use of protective reagents such as Pluronic F68. John Wiley and Sons Inc. 2018-09-08 2018-11 /pmc/articles/PMC6334174/ /pubmed/30102764 http://dx.doi.org/10.1002/bit.26817 Text en © 2018 The Authors. Biotechnology and Bioengineering Published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle ARTICLES
Blas, Peter
Tolner, Berend
Ward, John
Chester, Kerry
Hoare, Mike
The use of a surface active agent in the protection of a fusion protein during bioprocessing
title The use of a surface active agent in the protection of a fusion protein during bioprocessing
title_full The use of a surface active agent in the protection of a fusion protein during bioprocessing
title_fullStr The use of a surface active agent in the protection of a fusion protein during bioprocessing
title_full_unstemmed The use of a surface active agent in the protection of a fusion protein during bioprocessing
title_short The use of a surface active agent in the protection of a fusion protein during bioprocessing
title_sort use of a surface active agent in the protection of a fusion protein during bioprocessing
topic ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334174/
https://www.ncbi.nlm.nih.gov/pubmed/30102764
http://dx.doi.org/10.1002/bit.26817
work_keys_str_mv AT blaspeter theuseofasurfaceactiveagentintheprotectionofafusionproteinduringbioprocessing
AT tolnerberend theuseofasurfaceactiveagentintheprotectionofafusionproteinduringbioprocessing
AT wardjohn theuseofasurfaceactiveagentintheprotectionofafusionproteinduringbioprocessing
AT chesterkerry theuseofasurfaceactiveagentintheprotectionofafusionproteinduringbioprocessing
AT hoaremike theuseofasurfaceactiveagentintheprotectionofafusionproteinduringbioprocessing
AT blaspeter useofasurfaceactiveagentintheprotectionofafusionproteinduringbioprocessing
AT tolnerberend useofasurfaceactiveagentintheprotectionofafusionproteinduringbioprocessing
AT wardjohn useofasurfaceactiveagentintheprotectionofafusionproteinduringbioprocessing
AT chesterkerry useofasurfaceactiveagentintheprotectionofafusionproteinduringbioprocessing
AT hoaremike useofasurfaceactiveagentintheprotectionofafusionproteinduringbioprocessing